Bone Biopsy Market Forecast till 2030

$4,950$7,250

The bone biopsy market is projected to register a CAGR of 5.25% during the gauge time frame.

SKU: MRFR230482 Category: Tag:

Description

Bone Biopsy Market Forecast till 2030

Market Overview

The bone biopsy market is projected to register a CAGR of 5.25% during the gauge time frame. Bone biopsy utilizes a needle and imaging direction to wipe out a little example of bone for assessment under a magnifying lens. Bone biopsies might be utilized to approve the conclusion of a bone problem, inspect an irregularity, lay out the reason for torment or disease, or separate bone growths from different circumstances. Developing interest in insignificantly obtrusive methodology is fuelling the development of the worldwide bone biopsy market. An insignificantly obtrusive methodology is the utilization of various procedures to work with less harm to the patient’s body. It has different advantages, for example, less employable and post-usable significant difficulties, less post-usable torment, abbreviated clinic stays, and quicker recuperation times.

The increase in the worldwide bone biopsy market is driven by the elements like the rising commonness of bone malignant growths and expanding acknowledgment of bone marrow biopsy for finding and the d treatment of lymphoma and leukemia illness. What’s more, further developing medical services foundations across arising nations sets out to reward freedom for the market. Notwithstanding, severe administrative approaches are probably going to limit market development.

Market Segmentation
Based on Type, the global Bone Biopsy Market is bifurcated into Needle Biopsy and Open Biopsy. MRI-Guided and CT-Guided products make up the market’s GUIDED category. For the identification of live tumors, lesions that cannot be seen by CT, and bone marrow lesions, a biopsy performed under MRI guidance is very helpful (after chemotherapy or radiation).
The End User segment is made up of hospitals and Clinics, Surgical Centres, and Others. Bone biopsy proceeds as a short-term technique in the clinic that typically takes under an hour and clinics are one of the primary contact focus and the most trustable choice for patients. The developing frequency and predominance of malignant growth, rising interest in negligibly obtrusive strategies, and enormous geriatric patient populace are driving the interest in the bone biopsy.

Regional Analysis
In North America, the bone biopsy market is credited to the rising predominance of bone problems like bone disease, osteoporosis osteomyelitis, and others. Additionally, the presence of good repayment approaches, advanced medical services foundation, and quick reception of cutting-edge clinical innovations in the region drive the regional market development during the gauge time frame.
Asia-Pacific is expected to enlist the most noteworthy development rate over the estimated period. This is because of the elements like further developing medical services framework, government drives, and the rising patient populace experiencing bone malignant growth, bone Contamination, osteoporosis, constant kidney infection, and other bone problems. For example, as indicated by the Global Osteoporosis Establishment, by
Major Players
The Key companies operating in a global Bone Biopsy Market are Argon Medical (US), Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF BONE CANCER

4.2.2 GROWING DEMAND FOR MINIMALLY INVASIVE PROCEDURES

4.2.3 INCREASING ACCEPTANCE OF BONE MARROW BIOPSY FOR DIAGNOSIS AND TREATMENT OF LYMPHOMA AND LEUKEMIA DISEASE

4.3 RESTRAINTS

4.4 OPPORTUNITIES

4.4.1 IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES REVIEW

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF BUYERS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19

5.3.1 IMPACT ON DEMAND

5.3.2 IMPACT ON SUPPLY CHAIN

6 GLOBAL BONE BIOPSY MARKET, BY TYPE

6.1 OVERVIEW

6.2 NEEDLE BIOPSY

6.3 OPEN BIOPSY

7 GLOBAL BONE BIOPSY MARKET, BY GUIDED

7.1 OVERVIEW

7.2 MRI-GUIDED

7.3 CT-GUIDED

8 GLOBAL BONE BIOPSY MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS AND CLINICS

8.3 SURGICAL CENTERS

8.4 OTHERS

9 GLOBAL BONE BIOPSY MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL BONE BIOPSY MARKET

10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BONE BIOPSY MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

10.6.2 PARTNERSHIP/COLLABORATION

10.7 MAJOR PLAYERS FINANCIAL MATRIX

10.7.1 SALES 2021

10.7.2 R&D EXPENDITURE (USD MILLION), 2021

11.1 ARGON MEDICAL

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 B. BRAUN MELSUNGEN AG

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 BECTON, DICKINSON, AND COMPANY

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 CARDINAL HEALTH

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 MERMAID MEDICAL GROUP

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 KIMAL PLC

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGIES

11.7 STRYKER

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 COOK MEDICAL

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS/S OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 REMINGTON MEDICAL

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 MERIT MEDICAL SYSTEMS

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 SWOT ANALYSIS

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Companies Mentioned

Argon Medical (US), Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US)

Reviews

There are no reviews yet.

Be the first to review “Bone Biopsy Market Forecast till 2030”